Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Dec. 11, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 22, 2010
Debt instruments principal amount			$ 1,466
Debt maturity date	Jun. 15, 2017
Common stock par value		$ 0.0005	$ 0.0005
Adjustments to reduce inventory for excess or obsolete inventory		$ 1,600	$ 501
Cash balance		441
Bank balance		551
Amount of bank balance covered by federal depository insurance		309
Amount of bank balance uninsured		242
Allowance for bad debt
Provision for sales allowances		108	83
Prepaid expenses and other current assets		263	854
Share-based compensation expense		$ 1	135	$ 1,000
Equity ownership interest		50.00%			50.00%
Advertising and incentive promotion expenses		$ 9,700	8,500	10,900
Research and development		575	1,078	$ 1,322
Estimated Future Sales Return [Member]
Accrued liabilities		1,200	1,400
Cooperative Incentive [Member]
Accrued liabilities		1,500	$ 786
TK Supplements [Member]
Adjustments to reduce inventory for excess or obsolete inventory		383
Potential Division Sale [Member]
Adjustments to reduce inventory for excess or obsolete inventory		$ 606
OTC Health Care [Member]
Revenue, percentage		84.00%	90.00%	94.00%
Secured Promissory Notes [Member]
Debt instruments principal amount		$ 1,500
Debt maturity date		Jun. 15, 2017
2015 Equity Line of Credit [Member]
Working capital		$ 2,800
Number of common stock issued during period		2,450,000
Common stock par value		$ 0.0005